세계의 약물감시 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Pharmacovigilance Market is presumed to reach the market size of nearly USD 19.3 Billion by 2032 from USD 8.83 Billion in 2023 with a CAGR of 9.08% under the study period 2024-2032.

Pharmacovigilance is a science related to the detection, collection, assessment, understanding, monitoring, and prevention of adverse effects or any other drug-related problem with the pharmaceutical products. An adverse drug reaction (ADR) is an adverse or harmful reaction of medicines that occurred during its clinical use. The adverse reaction may be of various types including drug toxicity. Pharmacovigilance deals with understanding and identifying the harmful effects of pharmaceutical products and aids in reducing the risk to the patients. Pharmacovigilance is an unavoidable part of drug discovery and development procedures. With the growing consumption of medicines, the need for the proper pharmacovigilance is also accelerated.

MARKET DYNAMICS

The prime forces that are driving the global pharmacovigilance market include growing drug consumption, rapidly advancing drug discovery and development, and rising incidences of adverse drug reactions & drug toxicity. Furthermore, factors such as a growing preference for personalized medicine and a rising trend for outsourcing pharmacovigilance services are expected to foster the global market. The advancement in information systems and ADR databases is also supporting the growth of the pharmacovigilance market. COVID-19 pandemic is anticipated to stimulate the market more energetically, during the forecast period, as the global pharmaceutical manufacturers are working strenuously to discover the drug against the disease. However, supply chain disruption may agitate the global market for some period.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Pharmacovigilance. The growth and trends of Pharmacovigilance industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Pharmacovigilance market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Development

• Preclinical Studies
• Phase I
• Phase II
• Phase III
• Phase IV or Post Marketing Surveillance

By Type of Methods

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

By Type of Service

• In-house
• Contract Outsourcing

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pharmacovigilance market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmacovigilance market include Accenture Plc, Bristol-Myers Squibb, Clinquest Group B.V., Cognizant, Labcorp Drug Development, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, ICON Plc, IGATE Corporation, IMEDGlobal Corporation, Syneos Health, Novartis AG, Parexel International Corporation, Pfizer Inc., Pharmaceutical Product Development LLC. (PPD), IQVIA, Sanofi,. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. PHARMACOVIGILANCE - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Development
  • 3.7.2 Market Attractiveness Analysis By Type of Methods
  • 3.7.3 Market Attractiveness Analysis By Type of Service
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY DRUG DEVELOPMENT

• 5.1. Overview By Drug Development
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Drug Development
• 5.4. Preclinical Studies Historic and Forecast Sales By Regions
• 5.5. Phase I Historic and Forecast Sales By Regions
• 5.6. Phase II Historic and Forecast Sales By Regions
• 5.7. Phase III Historic and Forecast Sales By Regions
• 5.8. Phase IV or Post Marketing Surveillance Historic and Forecast Sales By Regions

6. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY TYPE OF METHODS

• 6.1. Overview By Type of Methods
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Type of Methods
• 6.4. Spontaneous Reporting Historic and Forecast Sales By Regions
• 6.5. Intensified ADR Reporting Historic and Forecast Sales By Regions
• 6.6. Targeted Spontaneous Reporting Historic and Forecast Sales By Regions
• 6.7. Cohort Event Monitoring Historic and Forecast Sales By Regions
• 6.8. EHR Mining Historic and Forecast Sales By Regions

7. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY TYPE OF SERVICE

• 7.1. Overview By Type of Service
• 7.2. Historical and Forecast Data
• 7.3. Analysis By Type of Service
• 7.4. In-house Historic and Forecast Sales By Regions
• 7.5. Contract Outsourcing Historic and Forecast Sales By Regions

8. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PHARMACOVIGILANCE COMPANIES

• 9.1. Pharmacovigilance Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF PHARMACOVIGILANCE INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Accenture Plc
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Bristol-Myers Squibb
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Clinquest Group B.V.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Cognizant
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Labcorp Drug Development
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. F. Hoffmann-La Roche Ltd.
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. GlaxoSmithKline Plc
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. ICON Plc
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. IGATE Corporation
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. IMEDGlobal Corporation
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Syneos Health
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments
• 10.14. Novartis AG
  • 10.14.1 Company Overview
  • 10.14.2 Company Revenue
  • 10.14.3 Products
  • 10.14.4 Recent Developments
• 10.15. Parexel International Corporation
  • 10.15.1 Company Overview
  • 10.15.2 Company Revenue
  • 10.15.3 Products
  • 10.15.4 Recent Developments
• 10.16. Pfizer Inc.
  • 10.16.1 Company Overview
  • 10.16.2 Company Revenue
  • 10.16.3 Products
  • 10.16.4 Recent Developments
• 10.17. Pharmaceutical Product Development LLC. (PPD)
  • 10.17.1 Company Overview
  • 10.17.2 Company Revenue
  • 10.17.3 Products
  • 10.17.4 Recent Developments
• 10.18. IQVIA
  • 10.18.1 Company Overview
  • 10.18.2 Company Revenue
  • 10.18.3 Products
  • 10.18.4 Recent Developments
• 10.19. Sanofi
  • 10.19.1 Company Overview
  • 10.19.2 Company Revenue
  • 10.19.3 Products
  • 10.19.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies